Caseous lymphadenitis (CLA) caused by Corynebacterium pseudotuberculosis is a worldwide disease of sheep and goats and is characterized by development of pyogranulomas in lymph nodes and lungs. Control of this disease by vaccination remains controversial, although toxoid vaccines are now commercially available in some countries. To determine the efficacy of acquired immunity to control CLA, the effect of primary infection on subsequent challenge exposure was investigated. Adult seronegative ewes were primarily inoculated with a streptomycin-sensitive strain of C pseudotuberculosis on the external part of the left ear and thereafter challenge-exposed by inoculation of the streptomycin-resistant strain 19R in the right ear. This protocol indicated that primary infection with at least 10(7) viable bacteria induced strong protection against subsequent challenge exposure; the ewes with primary infection did not develop lesions as a result of challenge exposure, whereas immune-naive ewes developed numerous pyogranulomas in the right car, in lymph nodes draining the inoculation site, and in the lungs. However, ewes with primary infection remained carriers of the disease as a result of primary inoculation. These results offer experimental support for development of more effective vaccination to control CLA in sheep and goats, and this model indicates that animals with primary infection can be used as positive controls for protection when testing a candidate vaccine against CLA.
Download full-text PDF |
Source |
---|
J Am Soc Nephrol
January 2025
Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia.
Background: People with chronic kidney disease (CKD) have a higher risk for progression to tuberculosis disease following infection with Mycobacterium tuberculosis. We produced a nationwide incidence estimate and description of tuberculosis among people with kidney failure.
Methods: We completed a cross-sectional descriptive analysis of people with a reported case of tuberculosis in the United States between 2010 and 2021.
Hepatology
January 2025
Genome Medical Science Project, National Center for Global Health and Medicine, Ichikawa, Japan.
Background Aims: Hepatitis B virus (HBV) leads to severe liver diseases, such as cirrhosis and hepatocellular carcinoma. Identification of host factors that regulate HBV replication can provide new therapeutic targets. The discovery of sodium taurocholate cotransporting polypeptide (NTCP) as an HBV entry receptor has enabled the establishment of hepatic cell lines for analyzing HBV infection and propagation.
View Article and Find Full Text PDFHernia
January 2025
Department of Surgery, Shouldice Hospital, Markham, ON, Canada.
Purpose: The aim of the study was to evaluate operative time and postoperative complications of 4 post-training specialized surgeons.
Methods: This was a pilot retrospective chart review to determine the learning curve of a Shouldice primary inguinal hernia repair (Shouldice Repair) of 4 post-training specialized surgeons, at the Shouldice Hospital. The first 300 Shouldice Repairs (early learning block) were compared to their 900-1,000 repairs as the primary operating surgeon (late learning block).
Arch Orthop Trauma Surg
January 2025
Trauma Unit, Department of Surgery, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
Introduction: Surgical site infections (SSI) are one of the more severe complications following ankle surgery. It is associated with worse outcomes and re-admissions. Therefore, identification of risk factors is essential.
View Article and Find Full Text PDFHernia
January 2025
Department of Minimally Invasive Surgery, National University Hospital, Bukit Timah, Singapore.
Background: Given the increasing prevalence of antiplatelet agent use and the lack of high-quality evidence, the CAPTAIN trial aimed to investigate the safety and provide recommendations on continuing acetylsalicylic acid perioperatively in patients undergoing elective laparoscopic totally extraperitoneal inguinal hernia repair (LIHR).
Methods: The CAPTAIN trial was a multicentre, surgeon blind, randomized controlled trial conducted from April 2016 to April 2023. Patients undergoing LIHR were eligible for inclusion.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!